BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences (BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with gross profit of $5.1 million and a net loss of $3.7 million ($0.17/share). Cash rose to $16.2 million. The company revised 2026 revenue guidance to $37 million to $40 million and expects consolidated EBITDA losses of $3 million to $5 million, citing a shift toward CDMO growth and a rare fragrance supply agreement.
How this was made
The 30-second read
Why it matters
The key tradable update is the downward revision to 2026 revenue guidance and the associated EBITDA loss outlook, counterbalanced by a higher cash balance and a newly secured fragrance CDMO supply/manufacturing agreement with 2027-2028 potential revenue.
Market read
Traders can reassess BHST’s 2026 growth and profitability trajectory based on the guidance reset, cash runway improvement, and the timing of fragrance production starting in 1H 2027.
What to watch
Investors may underweight the cash increase to $16.2M and the Stage 2 saffron development funding, both of which can reduce near-term financing risk while CDMO milestones progress.
Background
BioHarvest Sciences held its Q2 2026 financial results call, emphasizing Botanical Synthesis platform progress and a strategic pivot toward higher-margin CDMO opportunities.
Ticker impact
BioHarvest reported Q2 results and revised full-year 2026 revenue guidance to $37M-$40M, plus EBITDA loss outlook changes.
Likely choppy trading with downside risk if investors focus on the lowered revenue range and VINIA EBITDA loss widening, partially offset by the cash increase and new fragrance CDMO supply agreement.
The article contains multiple forward-looking datapoints (revised revenue and EBITDA loss ranges, cash balance, and a new 20-ton fragrance supply agreement) that can reprice expectations, but it is a transcript-style earnings call rather than a single surprise datapoint like a contract award headline or financing.
Market effects
Highlights a biotech/nutraceutical shift toward CDMO and royalty/licensing models, which may influence sentiment toward similar platform companies.
Israel Innovation Authority grant underscores continued Israeli biotech funding support, but likely limited immediate market impact.
Rare fragrance and plant-cell manufacturing execution themes are globally relevant for supply-chain and manufacturing-capacity narratives.
Counterpoint
The revenue guidance cut may be more about timing and resource reallocation than demand weakness, and the CDMO contract plus manufacturing ramp could accelerate later-year profitability.
Key entities
- companyBioHarvest Sciences
Reported Q2 2026 results and revised 2026 guidance, including CDMO and VINIA outlook changes, plus a new rare fragrance CDMO supply agreement.
- executiveZaki Rakib
CEO who discussed media cost inflation, marketing spend reallocation, and the rationale for guidance revisions.
- partnerTate & Lyle
Expanded collaboration for additional plant-based sweetener molecules beyond the original compound.
